Why XOMA (XOMA) Stock Is Surging Today

NEW YORK (TheStreet) -- XOMA Corporation (XOMA) shares are up 18.85% to $4.54 on Tuesday after being upgraded to "buy" from "hold" by analysts at MLV & Co.

The upgrade follows the company's announcement that it was finalizing plans for its gevokizumab Phase 3 program.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. 

The program was finalized following a meeting with regulators from the FDA.

"Our call is based on valuation and optimism around positive upcoming data from the P3 trial for lead asset gevokizumab (gevo) expected sometime mid-year. On positive data, we're expecting ~15-20% of upside to the stock, with potential for additional upside in the form of two other P3 readouts for gevo expected by year-end," MLV said.

The firm maintained its $7 price target on the shares.

XOMA Chart

XOMA data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

XOMA (XOMA) Weak On High Volume

XOMA (XOMA) Weak On High Volume

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Surges in After-Hours Trading on Q4 Results

Xoma Stock Surges in After-Hours Trading on Q4 Results

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million